Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

Jun 29 2010

Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced top-line results from a Phase II placebo and positive comparator-controlled, parallel-arm, double-blind, dose-response clinical trial of the novel, investigational NR2B-selective NMDA (N-methyl D-aspartate) receptor antagonist, radiprodil (RGH-896), for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPNP). Treatment with radiprodil did not show statistically significant or clinically meaningful reductions in mean daily pain scores, the primary endpoint, compared to placebo for any of the dosages studied.

The companies will review the complete study database over the coming weeks to determine the appropriate next steps regarding the development of radiprodil.